Identification of LIMK2 as a therapeutic target in castration resistant prostate cancer

This study identified LIMK2 kinase as a disease-specific target in castration resistant prostate cancer (CRPC) pathogenesis, which is upregulated in response to androgen deprivation therapy, the current standard of treatment for prostate cancer. Surgical castration increases LIMK2 expression in mous...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer letters 2019-04, Vol.448, p.182-196
Hauptverfasser:	Nikhil, Kumar, Chang, Lei, Viccaro, Keith, Jacobsen, Max, McGuire, Callista, Satapathy, Shakti R., Tandiary, Michael, Broman, Meaghan M., Cresswell, Gregory, He, Yizhou J., Sandusky, George E., Ratliff, Timothy L., Chowdhury, Dipanjan, Shah, Kavita
Format:	Artikel
Sprache:	eng
Schlagworte:	Analysis of Variance Animals Cancer therapies Castration Castration resistant prostate cancer Chemotherapy CRISPR Experiments Feedback Hypoxia Hypoxia - metabolism Immunoglobulins Kinases Lim Kinases - metabolism LIMK2 Male Malignancy Medical research Metastasis Mice Molecular Targeted Therapy - methods mRNA Phosphorylation Plasmids Prostate cancer Prostatic Neoplasms, Castration-Resistant - metabolism Prostatic Neoplasms, Castration-Resistant - pathology Proteins RNA, Mitochondrial - metabolism Software Therapeutic applications Toxicity Tumorigenesis Tumors Twist-Related Protein 1 TWIST1 Ubiquitin
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!